eccogene glp 1 Announces Positive Topline Results from Phase 1b Trial of Elecoglipron (AZD5004/ECC5004), an Oral GLP-1 Receptor Agonist, in Adult Participants Living with Obesity/Overweight, with or without Type 2 Diabetes in China Elecoglipron Shows Positive Results in

This study employed a multi-omics approach, integrating transcriptomic, metabolomic, and gut microbiota analyses, to identify key pathways and interactions underlying these metabolic disturbances (Song X

We utilize a specific class of weight loss medication known as GLP-1 and GIP receptor agonists

GLP-1RAs Reduce Opioid Overdose and Alcohol Intoxication A large retrospective study of patient health records for Loyola University Chicago shows a 40% drop in opioid overdoses and a 50% drop in alcohol intoxication among people who received GLP-1RAs (typically for diabetes or obesity)

Within this database, they identified 638,501 individuals with a prior occurrence of acute pancreatitis